Platelet function profiles in patients with diabetes mellitus (Q38081078)

28 August 2017

Platelet function profiles in patients with diabetes mellitus (English)

1 reference

28 August 2017

Fabiana Rollini

1

1 reference

28 August 2017

Francesco Franchi

series ordinal

2

1 reference

28 August 2017

Ana Muñiz-Lozano

series ordinal

3

1 reference

28 August 2017

Dominick J Angiolillo

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

13 February 2013

1 reference

Journal of Cardiovascular Translational Research

28 August 2017

1 reference

28 August 2017

6

1 reference

28 August 2017

329-345

1 reference

28 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s12265-013-9449-0

28 August 2017

0 references

cites work

Clinical practice. Diagnosis of diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Pathobiology and cell interactions of platelets in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet dysfunction in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet activation in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Diabetes and antiplatelet therapy in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Atherothrombosis and high-risk plaque: part I: evolving concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Factors contributing to increased platelet reactivity in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Hyperglycemia: a prothrombotic factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Advanced glycation end products, oxidant stress and vascular lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Intensive versus conventional glucose control in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Insulin, insulin resistance, and platelet signaling in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet aggregation in obese and diabetic subjects: association with leptin level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet dysfunction in central obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effects of VLDL and remnant particles on platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Increased intracellular calcium mobilization in platelets from patients with type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Oxidative stress and platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet antioxidant enzymes in insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Hydrogen peroxide and peroxynitrite enhance Ca2+ mobilization and aggregation in platelets from type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Advanced glycation endproducts--role in pathology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Large Platelets Circulate in an Activated State in Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Aspirin for primary prevention of cardiovascular events in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Cyclooxygenase-1 haplotype modulates platelet response to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Diabetes, vascular complications and antiplatelet therapy: open problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Variability in responsiveness to oral antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet thrombin receptor antagonism and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Pharmacology of emerging novel platelet inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Cangrelor: a review on its mechanism of action and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Elinogrel: pharmacological principles, preclinical and early phase clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting St

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Vorapaxar in the secondary prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Impacto del tratamiento adyuvante con cilostazol comparado con dosis altas de mantenimiento de clopidogrel en pacientes con diabetes mellitus y respuesta subóptima

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9449-0

Altered cellular Ca2+ and Na+ transport in diabetes mellitus

21 January 2018

1 reference

12 December 2020

Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein

1 reference

12 December 2020

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

1 reference

12 December 2020

ADP receptors of platelets and their inhibition

1 reference

12 December 2020

Glycated low density lipoproteins modify platelet properties: a compositional and functional study

1 reference

12 December 2020

Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations

1 reference

12 December 2020

Platelet insulin receptor

1 reference

12 December 2020

Alterations of adenine nucleotide metabolism and function of blood platelets in patients with diabetes

1 reference

12 December 2020

Clopidogrel response variability: current status and future directions.

1 reference

12 December 2020

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

12 December 2020

Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease

1 reference

12 December 2020

Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?

1 reference

12 December 2020

The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes

1 reference

12 December 2020

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

1 reference

12 December 2020

Endogenously generated reactive oxygen species reduce PMCA activity in platelets from patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus

1 reference

12 December 2020

What cardiologists need to know about diabetes.

1 reference

12 December 2020

Trial of repeated low-dose aspirin in diabetic angiopathy

1 reference

12 December 2020

The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin

1 reference

12 December 2020

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

12 December 2020

Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes.

1 reference

12 December 2020

Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia

1 reference

12 December 2020

Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus

1 reference

12 December 2020

Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis

1 reference

12 December 2020

Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins

1 reference

12 December 2020

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

1 reference

12 December 2020

Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood

1 reference

12 December 2020

Von Willebrand factor in diabetic angiopathy

1 reference

12 December 2020

Platelets from diabetic subjects show diminished sensitivity to prostacyclin

1 reference

12 December 2020

Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles.

1 reference

12 December 2020

Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo

1 reference

12 December 2020

Effects of insulin on calcium metabolism and platelet aggregation

1 reference

12 December 2020

Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo")

1 reference

12 December 2020

Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention

1 reference

12 December 2020

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

1 reference

12 December 2020

Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions

1 reference

12 December 2020

Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity

1 reference

12 December 2020

Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus

1 reference

12 December 2020

Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis

1 reference

12 December 2020

Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus

1 reference

12 December 2020

Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria

1 reference

12 December 2020

Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication

1 reference

12 December 2020

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

10.1007/S12265-013-9449-0

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference